Company Profile: ARIZ Precision Medicine
Overview
ARIZ Precision Medicine is a biotechnology firm founded in 2015, located in Davis, California. The company is devoted to developing innovative cancer therapies using precision medicine principles. ARIZ's methodologies leverage biological and nanotechnologies to target and treat cancer at its roots with a focus on precision ligand-targeted therapies.
Key Technologies and Approach
The company's unique approach involves breaking down the complex issue of cancer into smaller, more manageable components, allowing for the creation of drugs that specifically address the initial oncogenic errors. ARIZ's technology is designed to deliver highly targeted drugs that induce apoptosis in cancer cells while minimizing damage to healthy cells.
Recent Developments
- Collaboration with NATA: In November 2024, ARIZ partnered with the UK's Medical Research Council's Nucleic Acid Therapy Accelerator to further develop nucleic acid therapies for cancer treatment.
- Patent Achievements: As of August 2024, ARIZ secured a significant patent for its siRNA cancer therapeutic, bolstering its intellectual property portfolio.
- Funding Success: The company acquired multiple rounds of financing, including a $110,000 investment in November 2024 from AngelCon investors and seed financing totaling $2.5 million in November 2020.
Financials & Workforce
ARIZ Precision Medicine generates an estimated annual revenue of $620,000 and employs four individuals. There has been no reported growth in employee numbers over the past year.
Leadership Team
- Brad Niles, PhD: CEO with two decades of experience in cancer research and product development, overseeing the company's strategic vision.
- Lonnie Bookbinder, PhD, MBA: Founder, Chairman, and CEO, with 47 years in pharmaceutical leadership and entrepreneurship.
- Glenn Kazo: Chief Business Officer, founder of Enzon, and inventor of Pegylation technology, contributing to successful IPOs and raising over $500 million.
Scientific Advisory Board
- Shi Huang, PhD: Known for discovering the PRDM family, enhancing ARIZ's capabilities in targeting oncogenes.
- H. Michael Shepard, PhD: Inventor of Herceptin, providing insight into drug development.
- Dean Felsher, MD, PhD: Oncogene researcher at Stanford School of Medicine, offering oncological expertise.
Board Members
- Lokesh Sikaria: Founder and Managing Director at Moneta Ventures, key in venture capital investment.
- Kevin Nagle: Co-owner of the Sacramento Kings and Sac Republic FC, contributing investment and strategic guidance.
Vision and Impact
ARIZ's mission is to revolutionize cancer therapy by developing treatments that stop cancer at its root causes, thus preventing growth and metastasis. Through strategic collaborations and advancements in intellectual property, ARIZ aims to enhance global cancer patient outcomes.
Competitive Landscape
Key Competitors
- DiaCarta: Specializes in precision diagnostics for cancer gene mutations, with an estimated $4.4M in revenue and a workforce of 57 employees.
- Mission Bio: Generates approximately $21.2M in revenue with 137 employees, known for its single-cell genomics platform for cancer biomarker development.
- Quadrants Scientific: Provides analytical testing services, with $0.9M revenue and a staff of 6.
Additional Competitors
- Vor Biopharma: Innovates treatments for blood cancers through cell and genome engineering.
- Avstera Therapeutics: Focuses on oncology, addressing immunological challenges in cancer treatment.
Strategic Position
ARIZ is dedicated to advancing the frontier of personalized medicine, emphasizing gene and protein modification technologies. By utilizing Nobel prize-winning methodologies, ARIZ develops targeted cancer therapies with minimal adverse effects. The company intends to advance drug candidates into clinical trials, aiming to establish data and intellectual property conducive to forming partnerships with pharmaceutical companies.
ARIZ Precision Medicine, though smaller in scale, is firmly committed to innovation in cancer treatment. Its strategy of harnessing advanced biotechnologies to tackle previously undruggable targets sets it apart in a competitive landscape.
